



## Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

November 25, 2024

WALTHAM, Mass., Nov. 25, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that will participate in a fireside chat and investor meetings at the 7th Annual Evercore ISI HealthCONx Conference. Details of the fireside are as follows:

- Tuesday, December 3, 2024, at 7:30 a.m. Eastern time

To access this webcast, please visit the "Events & Presentations" page within the Investors section of the Spyre website at [ir.spyre.com](http://ir.spyre.com). An archive of the webcast will be available for replay following the end of the conference.

### About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting  $\alpha 4\beta 7$ , TL1A, and IL-23. For more information, visit Spyre's website at [www.spyre.com](http://www.spyre.com).

Follow Spyre Therapeutics on social media: [@spyretx](#) and LinkedIn

SOURCE Spyre Therapeutics, Inc.